{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-242398","form_type":"8-K","ticker":"TXMD","cik":"0000025743","company_name":"TherapeuticsMD, Inc.","filed_at":"2022-09-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:57.720760+00:00","generated_at":"2026-06-23T11:26:39.924876+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"TherapeuticsMD CEO departs; co-founder & CBO named interim co-CEOs; strategic review ongoing","bullets":["CEO Hugh O'Dowd departed Sept 6, 2022; termination without 'Good Cause' triggers severance.","Dr. Brian Bernick (co-founder, Chief Scientific/Medical Officer) and Mark Glickman (Chief Business Officer) named Interim Co-CEOs.","Tommy Thompson, former Chairman since 2012, appointed Executive Chairman.","Press release states the Company continues its robust strategic alternatives process."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-242398","json":"https://secwatch.observer/filing/0001193125-22-242398.json","markdown":"https://secwatch.observer/filing/0001193125-22-242398.md","text":"https://secwatch.observer/filing/0001193125-22-242398.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/25743/000119312522242398/0001193125-22-242398-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/25743/000119312522242398/d395778d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-23T11:26:39.924876+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"04358fadbf","claim":"Tommy Thompson was appointed as Executive Chairman at TherapeuticsMD, Inc..","evidence_excerpt":"the Board appointed The Honorable Tommy Thompson, who previously served as the Company’s Chairman of the Board, as the Executive Chairman of the Board.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/25743/000119312522242398/0001193125-22-242398-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Executive Chairman"}],"fact_type":"executive_change"},{"claim_id":"0aae8d7994","claim":"Mark Glickman was appointed as Interim Co-Chief Executive Officer at TherapeuticsMD, Inc..","evidence_excerpt":"On September 6, 2022, the board of directors (the “Board”) of TherapeuticsMD, Inc., a Nevada corporation (the “Company”), appointed Dr. Brian Bernick, the Company’s co-founder and Chief Scientific and Medical Officer, and Mr. Mark Glickman, the Company’s Chief Business Officer, as the Company’s Interim Co-Chief Executive Officers","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/25743/000119312522242398/0001193125-22-242398-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Interim Co-Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"e292e25807","claim":"Hugh O'Dowd departed as Chief Executive Officer at TherapeuticsMD, Inc..","evidence_excerpt":"Mr. O’Dowd’s separation as the Company’s Chief Executive Officer is a termination without “Good Cause,”","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/25743/000119312522242398/0001193125-22-242398-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"termination without 'Good Cause'"},{"label":"Role","value":"Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"e4bbff3ef7","claim":"Brian Bernick was appointed as Interim Co-Chief Executive Officer at TherapeuticsMD, Inc..","evidence_excerpt":"On September 6, 2022, the board of directors (the “Board”) of TherapeuticsMD, Inc., a Nevada corporation (the “Company”), appointed Dr. Brian Bernick, the Company’s co-founder and Chief Scientific and Medical Officer, and Mr. Mark Glickman, the Company’s Chief Business Officer, as the Company’s Interim Co-Chief Executive Officers","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/25743/000119312522242398/0001193125-22-242398-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Interim Co-Chief Executive Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}